Abstract
Myotonic dystrophy type 1 (DM1) is an incurable multisystem disease caused by a CTG-repeat expansion in the DM1 protein kinase (DMPK) gene. The OPTIMISTIC clinical trial demonstrated positive and heterogenous effects of cognitive behavioral therapy (CBT) on the capacity for activity and social participations in DM1 patients. Here, we performed mRNA sequencing of full blood for 27 patients of the OPTIMISTIC cohort before and after the CBT intervention. We identified 608 genes for which their expression was significantly associated with the disease causing CTG-repeat expansion, as well as 1176 genes significantly associated with the average clinical response towards the intervention. Remarkably, all 97 genes significantly associated with both returned to more normal levels in patients who benefited most from CBT. This trend was consistent with the difference observed between DM1 patients and controls in an earlier study of blood mRNA expression levels, singling these genes out as candidate biomarkers for therapy response. Together these results highlight the ability to find disease relevant information in full blood of DM1 patients, opening new avenues to monitor therapy effects.
Competing Interest Statement
R. van Cruchten reports no disclosures relevant to the manuscript. D. van As reports no disclosures relevant to the manuscript. J.C. Glennon reports no disclosures relevant to the manuscript. B. G. M. van Engelen received fees (to the institution) and non-financial support from Fulcrum Therapeutics, Facio Therapies and Arrowhead Pharmaceuticals during the conduct of the study. In addition, he received grant support from the FP7 European Union grand OPTIMISTIC, Marigold Foundation Canada, Prinses Beartrix Spierfonds, Spieren voor Spieren, FSHD Stichting and FSHD Society. He also has an unpaid function as head of the scientific advisory board for Euro-DyMA. P. A. C. 't Hoen reports no disclosures relevant to the manuscript.
Funding Statement
This study was funded by the European Union's Horizon 2020 research and innovation programme "ERA-NET rare disease research implementing IRDiRC objectives - N 643578" via the Dutch research funding agency ZON-MW, through the E-Rare Joint Transnational Call JTC 2018 "Translational Research Projects on Rare Diseases" (ReCognitION project: Recognition and validation of druggable targets from the response to Cognitive Behaviour Therapy in Myotonic Dystrophy type 1 patients from integrated -omics networks). This study was also partially funded by the European Union Seventh Framework Program, under grant agreement no. 305697 (the Observational Prolonged Trial In Myotonic dystrophy type 1 to Improve Quality of Life Standards, a Target Identification Collaboration [OPTIMISTIC] project).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The analyses presented in this work are part of the European OPTIMISTIC project. Prior to participation in the OPTIMISTIC study, all participants had provided written informed consent, including a consent for the use of their pseudo anonymized blood, urine and DNA samples. Ethical approval of the OPTIMISTIC project was given from National Research Ethics Service Committee North East - Sunderland (UK), Comite de Protection des Personnes ile de France V (France); Ethikkommission bei der LMU Munchen (Germany); Concernstaf Kwaliteit en Veiligheid Commissie Mensgebonden Onderzoek Regio Arnhem- Nijmegen (Netherlands).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Several authors of this publication are members of the Radboudumc Center of Expertise for neuromuscular disorders (Radboud-NMD), Netherlands Neuromuscular Center (NL-NMD) and the European Reference Network for rare neuromuscular diseases (EURO-NMD).
Remco.vanCruchten{at}Radboudumc.nl
Daniel.vanAs{at}radboudumc.nl
Jeffrey.Glennon{at}ucd.ie
Baziel.vanEngelen{at}radboudumc.nl
Data Availability
All raw sequencing data and associated genotype/phenotype/experimental information is stored in the European Genome-phenome Archive (EGA) under controlled access with Dataset ID EGAS00001005830